Early response in the treatment of invasive candida disease, length of stay on the intensive care unit and projected costs with once-weekly rezafungin antifungal therapy

Candidaemia and invasive candidiasis (IC) remain significant causes of morbidity and mortality. The associated health economic burden is largely due to prolonged hospital and intensive care unit (ICU) stays. Rezafungin is a next-generation once-weekly echinocandin demonstrating a prolonged half-life and high front-loaded plasma exposures.